A recent narrative review looks at the most effective and emerging options for diagnosing and treating basal cell carcinoma.

Medicus Pharma (NASDAQ:MDCX) said on Friday it has submitted an application to the US Food and Drug Administration seeking ...

Please provide your email address to receive an email when new articles are posted on . The overall cure rate among patients that used Metvix following curettage was 90.3%. Adverse events were ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Five years after treatment, results showed a freedom ...

Basal cell carcinoma is the most common malignancy in humans, and it is also the mostfrequent periocular malignancy. Although a slow-growing tumor, it can lead to significant morbidityin the ...

Red light photodynamic therapy (PDT) with 10% aminolevulinic acid (ALA) tamed superficial basal cell carcinoma (BCC) in a phase 3 trial with no new safety concerns. Significantly higher clearance ...